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Abstract
PI3K signaling plays important roles in cell differentiation, proliferation, and migration. Increased
mutations and expression levels of PI3K are hallmarks for the development of certain cancers.
Pharmacological targeting of PI3K activity has also been actively pursued as a novel cancer
therapeutic. Consequently, measurement of PI3K activity in different cell types or patient samples
holds the promise as being a novel diagnostic tool. However, the direct measurement of cellular
PI3K activity has been a challenging task. We report here the characterization of two fluorescent
PIP2 derivatives as reporters for PI3K enzymatic activity. The reporters are efficiently separated
from their corresponding PI3K enzymatic products through either thin layer chromatography
(TLC) or capillary electrophoresis (CE), and can be detected with high sensitivity by fluorescence.
The biophysical and kinetic properties of the two probes are measured, and their suitability to
characterize PI3K inhibitors is explored. Both probes show similar capacity as PI3K substrates for
inhibitor characterization, yet also possess distinct properties that may suggest their different
applications. These characterizations have laid the groundwork to systematically measure cellular
PI3K activity, and have the potential to generate molecular fingerprints for diagnostic and
therapeutic applications.
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1. Introduction
Phosphatidylinositides (PIs) are not only integral components of cell membranes, but also
among the most versatile endogenous signaling molecules 1. Dynamic changes of PIs in the
membranes, particularly phosphatidylinositol 4,5-bisphosphate (PIP2) and
phosphatidylinositol 3,4,5-trisphosphate (PIP3), are fundamental to many functional
processes including cell proliferation and migration 2. Phosphatidylinositol 3-kinase (PI3K)
catalyzes the phosphorylation of PIP2 to form PIP3 (Fig. 1A), while phosphatase and tensin
homolog (PTEN) dephosphorylates PIP3 to regenerate PIP2. Dysfunction of either PI3K or
PTEN has been linked to various diseases including cancer and diabetes 3–5. For example,
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glioblastoma, and pancreatic cancer 6–7. Consequently, small molecule PI3K inhibitors have
been actively pursued by pharmaceutical companies, and a number of compounds are in
clinical trials in oncology 8–10.
Although PI3K mutation and amplification have been firmly linked to various diseases,
whether and how genetic changes quantitatively impact enzymatic activity has not been well
established. This is partly due to the lack of suitable reporters and analytical tools to directly
measure cellular PI3K activity. Among the known methods for PI3K activity measurement,
radioactivity-based assays have been the most widely used 11. In these methods, the cells are
metabolically labeled with radioactive materials extracted with organic solvents. The lipid
fraction is separated by thin-layer chromatography (TLC) or high performance liquid
chromatography (HPLC) and detected by autoradiography. This approach has the advantage
of yielding quantitative results, and can be optimized to differentiate various lipids.
However, the assays are subject to cell-dependent differences in steady-state PI metabolism
and variable expression of PI3K. In addition, the incorporation efficiency of the radioactive
material may be low, and the sensitivity and specificity of the incorporation are limited. To
avoid metabolic labeling, matrix-assisted laser desorption ionization mass spectrometry
(MALDI-MS) has gained popularity for the rapid analysis of lipids in various biological
samples 12–13. A solvent extraction procedure of the lipids from the unpurified sample is
typically carried out prior to the MALDI-MS measurements. This method distinguishes
different lipids by their molecular weights; however, it does not distinguish between isomers
and requires sophisticated and expensive equipment. In addition, the dynamic range of lipid
concentrations in the cells makes the detection of low abundance lipids very difficult. The
phosphorylation of downstream proteins, such as protein kinase B (PKB, aka Akt), has also
been used to evaluate cellular PI3K activity. However, phosphorylation of Akt is an indirect
measure and confounded by the phosphorylation of Akt by other kinases. Finally,
fluorescently labeled pleckstrin homology (PH) domains have been used as an indirect assay
of the enzymatic activities of PI3K and PTEN. Cells are transfected with a PH domain that
binds to the substrate PI of interest, and is tagged with a fluorescent protein such as green
fluorescent protein (GFP) 14. A change in membrane-associated fluorescence signal will
occur if the level of the PI in the membrane changes. The major problems are that binding
specificity and affinity of the PI-binding domains towards various PIs are not very high, and
they are known to interact with other protein ligands. In addition, these molecularly
engineered cell-based assays cannot be used in clinical samples.
For in vitro assays, PI3K activity can be measured by monitoring the incorporation of 32P
into PIP2 to form radioactive PIP3. In addition, PH domains have been used as detectors in
measuring the production or localization of PIP3 15. In a competitive assay of PI3K activity,
the PIP2 is combined with PI3K and a PH domain that specifically detects the reaction
product PIP3. The reaction mixture is then added to a plate coated with PIP3 and the binding
of the probe is detected through fluorescence polarization or luminescence to reflect the
PI3K activity 16. These assays have gained popularity because of their relative simplicity
and suitability for high throughput screens, but such assays measure PI3K activity indirectly
and the accuracy is affected by many factors. These various limitations require new
techniques for analysis of PI3K activity directly and rapidly which can also be used in
clinically relevant situations where the amount of sample, such as from a patient, is limited.
To address this need, lipids tagged with fluorophores have been developed as substrates for
a variety of lipid metabolic enzymes, often with similar kinetics to the endogenous
substrates 17–18. BODIPY-tagged BODIPY-PIP2 (Fig. 1B) and fluorescein-tagged FL-PIP2
(Fig. 1C) have been used to image cellular localization of PIP2 19. Recently, Caliper
Lifesciences employed FL-PIP2 as a PI3K substrate for an in vitro assay in which
conversion of the FL-PIP2 to FL-PIP3 was monitored by electrophoretic chemical separation
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with laser-induced fluorescence detection in a microfabricated fluidic chip. Such highly-
sensitive, chemical separation techniques for monitoring phosphorylation lend themselves to
cell-based assays, and several examples using capillary electrophoresis (CE) with
fluorescent peptide- and lipid-based probes have been reported in single-cell biochemical
measurements 20–21. However, the amphiphilic nature of PI lipids renders them to potential
loss on the column during CE separation. Consequently, the accuracy of PI3K activity
measurement has to be validated. Toward the goal to adapt fluorescent PIP2 derivatives to
measure PI3K activity in patient samples, we carried out detailed kinetic studies using both
thin layer chromatography (TLC) and capillary electrophoresis (CE) analyses.
2. Materials and Methods
Materials
Purified PI3K (PIK3CA/PIK3R1) was obtained from Invitrogen. FL-PIP2 and FL-PIP3 were
purchased from Cayman Chemical. BODIPY-PIP3 was purchased from Echelon Bioscience.
BODIPY-PIP2 was synthesized according to the literature protocols 22. EOTrol LR was
obtained from Target Discovery. Wortmannin, LY294002, ATP, sodium deoxycholate
(SDC), 1-propanol and TLC plates with silica gel 60 were purchased from Sigma. Dynamic
light scattering data were recorded on a Wyatt DynaPro dynamic light scattering plate
reader. The fluorescence spectra were recorded with a QM-4 PTI spectra fluorometer with
rhodamine B (3 g/L in CH3OH) as the standard.
General PI3K Assay
The fluorescent PIP2 derivative (2 μM, final concentration) was added to the assay buffer
(60 μL, final volume) composed of MOPS (50 mM, pH 6.5), NaCl (100 mM), sodium
cholate (0.5 mM), DTT (1 mM), MgCl2 (10 mM), and ATP (2 mM). The reaction was
initiated by the addition of purified PI3K (2 ng/μL). After incubation at room temperature
for the indicated time, the enzymatic reaction was quenched by adding aqueous HCl (2.0 M,
25 μL). The resulting mixture was extracted with CHCl3/MeOH (v/v = 2:1, 250 μL) for 3
times. The organic layers were separated, combined, and concentrated under vacuum. The
resulting residue was re-suspended in CHCl3/MeOH (v/v = 1:1) for TLC analysis. TLC
plates (Merck, Silica Gel-60) were pretreated with a solvent system containing 1.2%
potassium oxalate and 1.2 mM EGTA in MeOH/water (v/v = 2:3) and heated at 110 °C for
20 min before use. The TLC plate was then developed in CHCl3/acetone/MeOH/AcOH/
water (v/v/v/v/v = 40:15:13:12:7) and scanned on a Typhoon 9400 Variable Mode Imager
(λex/λem = 488 nm/520 nm). The fluorescence intensity of different spots on the TLC plate
was quantified with ImageQuant software (V.5.0). Alternatively, the reaction mixture was
diluted in CHCl3/MeOH (v/v = 1:1, 10 μL) and spotted on a TLC plate directly for
separation and detection.
IC50 measurement of PI3K inhibitors
PI3K was incubated with the inhibitors in the assay buffer for 10 min at room temperature
before the assay was initiated by the addition of ATP. The final reaction mixture contained:
PIP2 (2 μM for BODIPY-PIP2 and 4 μM for FL-PIP2), ATP (20 μM), 2% DMSO, MOPS
(50 mM, pH 6.5), NaCl (100 mM), sodium cholate (0.5 mM), DTT (1 mM), MgCl2 (10
mM), and PI3K (2 ng/μL). After incubation at room temperature (90 min for BODIPY-PIP2,
and 180 min for FL-PIP2), the reaction mixture was diluted with CHCl3/MeOH (v/v = 1:1)
and analyzed as described above.
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CE analysis of lipid analytes was performed using a custom-built CE system with laser-
induced fluorescence detection as previously described 21. Fused-silica capillaries (40 cm
length, 50 μm i.d., 360 μm o.d., Polymicro Technologies, Phoenix, AZ) were used for the
analyte separations. A voltage of 16 kV was applied across the capillary during
electrophoresis. For CE analysis of the mixtures, sample volumes (0.6 nL) were loaded by
hydrodynamic injection. Separation of FL-PIP2, FL-PIP3, BODIPY-PIP2 and BODIPY-PIP3
was performed in 100 mM Tris, 10 mM SDC, 1 mM MgCl2, 30% 1-propanol, and 5%
EOTrol LR, at pH 8.5. Prior to each run, the capillary was flushed with 1 M NaOH for 3
min, deionized H2O for 3 min, and the separation buffer for 3 min using a pressurized
washing system at 20 psi. To directly compare the phosphorylation of reporters with
different fluorescent groups, BODIPY-PIP2 (1 μM) and FL-PIP2 (1 μM) were reacted with
PI3K for 1 h under the conditions described above. The reaction mixture was quenched by
adding 1-propanol and the sample was diluted 200-fold in water immediately prior to CE
analysis.
3. Results and Discussion
Characterization of FL-PIP2 and BODIPY-PIP2
PI3K catalyzes the phosphorylation of the endogenous PIP2 at the lipid-water interface
where the substrate PIP2 is in the lipid membranes while the phosphate donor ATP is in the
aqueous phase 23. Accordingly, most studies on PI3K reactions have been carried out in
lipid vesicles or micelles where the kinetic measurements are complex 11, 24. Because the
fluorescent PIP2 derivatives have shorter alkyl chains and are relatively more water soluble
compared to endogenous PIP2, we chose to characterize the two probes under soluble
conditions. When the lipid substrate was mono-dispersed in the assay buffer, the enzymatic
kinetics analysis followed the classical Michaelis-Menton equation. To ensure that the
probes did not form micelles under the assay conditions, the critical micelle concentration
(CMC), the amphiphile concentration at which the surface tension of the aqueous phase
reaches its minimum, was measured for both FL-PIP2 and BODIPY-PIP2. The light
scattering 25 of different concentrations of BODIPY-PIP2 and FL-PIP2 in deionized water at
25 °C was measured and plotted (Fig. 2A). The CMC of FL-PIP2 was approximately 225
μM while that of BODIPY-PIP2 was 65 μM. The CMC of endogenous PIP2 was also
measured by this method as 10 μM, which is consistent with the value obtained through
other methods reported in the literature 26.
The fluorescence excitation and emission spectra of both BODIPY-PIP2 and FL-PIP2 were
also measured (Fig. 2B). Both spectra of BODIPY-PIP2 and FL-PIP2 are similar as those of
the parent fluorophores BODIPY and fluorescein, respectively 27–29. Compared with FL-
PIP2, BODIPY-PIP2 possesses a higher extinction coefficient and narrower emission
bandwidth. The excitation maximum is 502 nm for BODIPY-PIP2 and 496 nm for FL-PIP2,
while the emission maximum is 511 nm for BODIPY-PIP2 and 516 nm for FL-PIP2. The
kinetic measurements of the fluorophore-tagged PIP2 and PIP3 in the subsequent
experiments were recorded with excitation at 488 nm and detected at 520 nm.
Validation of the PI3K reaction and separation of the reaction mixtures on TLC and CE
The canonical method for detection of PI3K enzymatic activity in vitro uses radioactive
ATP to incorporate 32P into the reaction product, which is subsequently separated from
other components in the reaction mixture on TLC and detected through
autoradiography 30–31. Likewise, we envisioned that the fluorescent PIP2 derivatives could
be used to report PI3K activity by first separating fluorescent PIP2 from its PI3K reaction
product on a TLC plate and then quantifying the ratio of the substrate to product through
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fluorescence detection. To optimize the separation efficiency, the TLC plates were
pretreated with potassium oxalate and EDTA followed by heating at 110 °C for 20 min. The
PI3K reaction mixture was extracted with CHCl3/MeOH (v/v = 2:1) four times and the
products were separated on TLC. Under suitable developing solutions (see methods), the
BODIPY-PIP2 and BODIPY-PIP3 were well separated (Fig. 3A, lane 2). The extraction
efficiency, as measured by fluorescence recovery, was approximately 97%. However, it was
not clear if BODIPY-PIP2 and BODIPY-PIP3 were extracted with the same efficiency,
raising concern about the accuracy of the measurement. Moreover, the extraction process
was tedious and time-consuming. We thus explored the possibility of analysis without the
extraction process. Thus, the reaction mixture was diluted with CHCl3/MeOH (v/v = 1:1) to
quench the PI3K-catalyzed reaction and directly separated by TLC (Fig. 3A, lane 3).
Interestingly, the separation of BODIPY-PIP2 from BODIPY-PIP3 proceeded with almost
identical efficiency. Likewise, the FL-PIP3 was also efficiently separated from FL-PIP2 on
TLC, either with or without the extraction process (Fig. 3B).
We have also attempted to separate a mixture of BODIPY-PIP2, BODIPY-PIP3, FL-PIP2,
and FL-PIP3 on TLC, but did not have success due to the similar Rf values between the FL-
tagged and BODIPY-tagged lipids. In contrast, these four fluorescent molecules could be
simultaneously measured by CE analysis. As shown in Fig. 3C, a mixture of BODIPY-PIP2,
BODIPY-PIP3, FL-PIP2, and FL-PIP3 were readily separated by CE. We then analyzed an
aqueous in vitro kinase reaction with PI3K after one hour incubation with both BODIPY-
PIP2 and FL-PIP2. Under the assay conditions used, 24 ± 5% of FL-PIP2 and 17 ± 3% of
BODIPY-PIP2 were phosphorylated (n = 5), (Fig. 3D). The difference in phosphorylation of
the two fluorescently labeled PIP2’s may be caused by greater loss of the more hydrophobic
BODIPY-labeled substrate during sample preparation and incubation thereby reducing its
concentration relative to its KM for PI3K. Under the assay conditions, the detection limits
for the fluorescently labeled PIP2 and PIP3 were approximately 0.3–1.2 × 10−12 for TLC
analysis and 1–10 × 10−20 mol for CE separation. These are comparable or better than the
detection limit (0.5–1 x10−12 mol) when the traditional radioactivity-based assay was used.
Kinetics analysis of PI3K activity with fluorescent PIP2 derivatives
To quantify the kinetic properties of BODIPY-PIP2 and FL-PIP2, we measured the KM and
Vmax of these two probes in the PI3K reaction. To ensure that the measurement was under
initial velocity conditions, we explored the effects of reaction time and amount of enzyme
on the conversion of BODIPY-PIP2 (Fig. 4A). When 1.2 ng/μL PI3K was used in the assay,
the conversion of BODIPY-PIP2 was within 10% after 30 min at room temperature while
the reaction product could still be easily detected and quantified by fluorescence intensity.
These conditions were thus used for subsequent experiments. In the cellular environment,
the ATP concentration is in the range of 1–10 mM. The KM for ATP with endogenous PIP2
as the substrate is in the range of 20–80 μM 30. Consequently, we used 2 mM ATP in all the
experiments for the KM and Vmax measurement.
To carry out the assay, PI3K was added to the assay buffer containing the fluorescent PIP2
derivative (2 μM) and ATP (2 mM). The concentration of the lipid substrate was varied to
generate a series of initial velocities. KM and Vmax were then calculated by fitting the data to
the Michaelis-Menton equation. Each experiment was carried out in duplicates and repeated
three times. The KM for FL-PIP2 was 44.8 ± 9.8 μM with a Vmax of 0.28 ± 0.07 pmol/ng/min
(Fig. 4B), while the KM for BODIPY-PIP2 was 68.7 ± 5.2 μM with a Vmax of 1.02 ± 0.33
pmol/ng/min (Fig. 4C).
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Measurement of the IC50 of PI3K inhibitors using fluorescent PIP2 derivatives
To test whether this in vitro assay system could be used to measure the effects of specific
pharmaceutical agents on PI3K activity, the IC50 of two known PI3K inhibitors were
measured using the two fluorescent PIP2 derivatives. Both LY294002 and wortmannin are
considered to be ATP competitive inhibitors, with LY294002 being reversible and
wortmannin irreversible 32–33. In contrast to the measurement for substrate kinetics where
ATP must be saturated, the IC50 measurement for ATP competitive inhibitors requires that
the ATP concentration is at or below the KM for ATP. Accordingly, the KM for ATP was
measured when FL-PIP2 (Fig. 5A) or BODIPY-PIP2 (Fig. 5B) was used in the PI3K
reaction. The KM, ATP was 66.9 ± 13.3 μM for FL-PIP2 and 24.8 ± 4.2 μM for BODIPY-
PIP2, while Vmax, ATP was 3.26 ± 0.22 pmol/μg/min for FL-PIP2 and 4.72 ± 0.21 pmol/μg/
min for BODIPY-PIP2. Based on these results, 20 μM ATP was used in the reaction mixture
to measure the IC50 of the PI3K inhibitors.
LY294002 or wortmannin were incubated with PI3K at room temperature for 10 min before
the enzyme was added to the assay buffer to initiate the reaction. When FL-PIP2 was used as
the PI3K substrate, the IC50 was 1.43 μM for LY294002 and 4.6 nM for wortmannin (Fig.
6A). Both of these values were consistent with those obtained with other methods 32, 34.
Similarly, the IC50 for LY294002 and wortmannin (Fig. 6B) were carried out with
BODIPY-PIP2 as the PI3K substrate. The IC50 was 1.41 μM and 6.2 nM, respectively.
In summary, we have established an in vitro assay system to directly measure PI3K activity.
This assay takes advantage of the ready separation of a fluorphore-tagged PIP2 derivative
from its PI3K reaction product on TLC or CE, and the high sensitivity of fluorescence
detection. Both FL-PIP2 and BODIPY-PIP2 have similar KM when used as the PI3K
substrate, and appear to function equally well to characterize PI3K inhibitors. On the other
hand, the Vmax for BODIPY-PIP2 is approximately 4-fold greater than that for FL-PIP2. In
addition, the BODIPY-PIP2 more easily forms micelles, a key character of endogenous
PIP2, than FL-PIP2 as judged by their CMCs. Finally, the BODIPY fluorophore offers many
advantages compared to fluorescein, including a narrow emission bandwidth, spectra that
are less sensitive to polarity and pH, longer excited state lifetimes, and a large two-photon
cross-section for multiphoton excitation. Taken together, these results suggest that both
fluorescent probes are effective PI3K substrates that can be used to measure PI3K activity,
but with fine differences. Given the important roles that PI3K plays in cell signaling and
disease, this work will facilitate the use of fluorescent PIP2 derivatives in measuring PI3K
activity in cell-based assays, including those using patient samples.
Acknowledgments
We thank the North Carolina University Cancer Research Fund and NIH (CA139599) for financial support.
References
1. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature.
2006; 443:651–657. [PubMed: 17035995]
2. Balla T, Szentpetery Z, Kim YJ. Phosphoinositide signaling: new tools and insights. Physiology
(Bethesda). 2009; 24:231–244. [PubMed: 19675354]
3. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an
intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007; 3:682–
693. [PubMed: 18046441]
4. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008; 9:162–176.
[PubMed: 18216772]
Huang et al. Page 6













5. Liu ZN, Roberts TM. Human tumor mutants in the p110 alpha subunit of PI3K. Cell Cycle. 2006;
5:675–677. [PubMed: 16627990]
6. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008; 455:1061–1068. [PubMed: 18772890]
7. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;
27:5497–5510. [PubMed: 18794884]
8. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer.
Nat Rev Drug Discov. 2009; 8:627–644. [PubMed: 19644473]
9. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J
Clin Oncol. 2010; 28:1075–1083. [PubMed: 20085938]
10. Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical
tools to drugs in the clinic. Cancer Res. 2010; 70:2146–2157. [PubMed: 20179189]
11. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem. 1998;
67:481–507. [PubMed: 9759495]
12. Hsu FF, Turk J. Characterization of phosphatidylinositol, phosphatidylinositol-4-phosphate, and
phosphatidylinositol-4,5-bisphosphate by electrospray ionization tandem mass spectrometry: A
mechanistic study. J Am Soc Mass Spectr. 2000; 11:986–999.
13. Wenk MR, et al. Phosphoinositide profiling in complex lipid mixtures using electrospray
ionization mass spectrometry. Nat Biotechnol. 2003; 21:813–817. [PubMed: 12808461]
14. Balla T, Varnai P. Visualizing cellular phosphoinositide pools with GFP-fused protein-modules.
Sci STKE. 2002; 2002:pl3. [PubMed: 11917154]
15. Gray A, Olsson H, Batty IH, Priganica L, Downes CP. Nonradioactive methods for the assay of
phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling
lipids in cell and tissue extracts. Anal Biochem. 2003; 313:234–245. [PubMed: 12605860]
16. Drees BE, et al. Competitive fluorescence polarization assays for the detection of phosphoinositide
kinase and phosphatase activity. Comb Chem High T Scr. 2003; 6:321–330.
17. Taylor GS, Dixon JE. An assay for phosphoinositide phosphatases utilizing fluorescent substrates.
Anal Biochem. 2001; 295:122–126. [PubMed: 11476556]
18. Zhong W, Murphy DJ, Georgopapadakou NH. Inhibition of yeast inositol phosphorylceramide
synthase by aureobasidin A measured by a fluorometric assay. FEBS Lett. 1999; 463:241–244.
[PubMed: 10606729]
19. Ozaki S, DeWald DB, Shope JC, Chen J, Prestwich GD. Intracellular delivery of phosphoinositides
and inositol phosphates using polyamine carriers. Proc Natl Acad Sci U S A. 2000; 97:11286–
11291. [PubMed: 11005844]
20. Borland LM, Kottegoda S, Phillips KS, Allbritton NL. Chemical analysis of single cells. Annu Rev
Anal Chem (Palo Alto Calif). 2008; 1:191–227. [PubMed: 20636079]
21. Mwongela SM, Lee K, Sims CE, Allbritton NL. Separation of fluorescent phosphatidyl inositol
phosphates by CE. Electrophoresis. 2007; 28:1235–1242. [PubMed: 17366487]
22. Chen J, Profit AA, Prestwich GD. Synthesis of Photoactivatable 1,2-O-Diacyl-sn-glycerol
Derivatives of 1-L-Phosphatidyl-D-myo-inositol 4,5-Bisphosphate (PtdInsP(2)) and 3,4,5-
Trisphosphate (PtdInsP(3)). J Org Chem. 1996; 61:6305–6312. [PubMed: 11667472]
23. Barnett SF, et al. Interfacial catalysis by phosphoinositide 3′-hydroxykinase. Biochemistry. 1995;
34:14254–14262. [PubMed: 7578025]
24. Carson JD, et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of
phosphoinositide 3-kinase. Biochem J. 2008; 409:519–524. [PubMed: 17877460]
25. Tsamaloukas AD, Beck A, Heerklotz H. Modeling the micellization behavior of mixed and pure n-
alkyl-maltosides. Langmuir. 2009; 25:4393–4401. [PubMed: 19366219]
26. Walsh JP, Suen R, Glomset JA. Arachidonoyl-diacylglycerol kinase. Specific in vitro inhibition by
polyphosphoinositides suggests a mechanism for regulation of phosphatidylinositol biosynthesis. J
Biol Chem. 1995; 270:28647–28653. [PubMed: 7499383]
27. Strandberg L, et al. Fluorescence studies on plasminogen activator inhibitor 1: reactive centre
cysteine mutants remain active after fluorophore attachment. Thromb Res. 1994; 76:253–267.
[PubMed: 7863476]
Huang et al. Page 7













28. Klonis N, Sawyer WH. Effect of solvent-water mixtures on the prototropic equilibria of fluorescein
and on the spectral properties of the monoanion. Photochem Photobiol. 2000; 72:179–185.
[PubMed: 10946570]
29. Schauenstein K, Schauenstein E, Wick G. Fluorescence properties of free and protein bound
fluorescein dyes. I. Macrospectrofluorometric measurements. J Histochem Cytochem. 1978;
26:277–283. [PubMed: 77868]
30. Carpenter CL, et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J
Biol Chem. 1990; 265:19704–19711. [PubMed: 2174051]
31. Carpenter CL, Cantley LC. Phosphoinositide kinases. Biochemistry. 1990; 29:11147–11156.
[PubMed: 2176895]
32. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994; 269:5241–
5248. [PubMed: 8106507]
33. Vanhaesebroeck B, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev
Biochem. 2001; 70:535–602. [PubMed: 11395417]
34. Wymann MP, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of
Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol. 1996; 16:1722–
1733. [PubMed: 8657148]
Huang et al. Page 8














Schematic illustration of the PI3K reaction. A. the endogenous PIP2 is phosphorylated at the
3′-OH to form PIP3; B, C. Chemical structures of fluorescent PIP2 derivatives BODIPY-
PIP2 (B) and FL-PIP2 (C).
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Biophysical characterization of FL-PIP2 and BODIPY-PIP2. A. Measurement of critical
micelle concentrations (CMCs) of FL-PIP2 and BODIPY-PIP2. B. Fluorescence excitation
and emission spectra of FL-PIP2 and BODIPY-PIP2.
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Separation of the PI3K reaction mixtures with fluorescent PIP2 derivatives through TLC or
CE analysis. A. the separation of the reaction mixture of FL-PIP2 on TLC. lane 1: FL-PIP2;
lane 2: the reaction mixture was extracted with CHCl3/MeOH (v/v = 2:1) before TLC
separation; lane 3: the reaction mixture was diluted with CHCl3/MeOH (v/v = 1:1) and
separated on TLC; lane 4: FL-PIP3. B. the separation of the reaction mixture of BODIPY-
PIP2 on TLC. lane 1: BODIPY-PIP2; lane 2: the reaction mixture was extracted with CHCl3/
MeOH (v/v = 2:1) before TLC separation; lane 3: the reaction mixture was diluted with
CHCl3/MeOH (v/v = 1:1) and separated on TLC; lane 4: BODIPY-PIP3. C. The separation
of a mixture of FL-PIP2, FL-PIP3, BODIPY-PIP2, and BODIPY-PIP3 by CE; D. A 1:1
mixture of FL-PIP2 and BODIPY-PIP2 were used for the PI3K reaction, and the reaction
mixture was separated by CE.
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Kinetic analysis of PI3K reaction with fluorescent PIP2 derivatives. A. The reaction progress
curves with different amounts of PI3K were used. B. Kinetic studies on PI3K reaction with
FL-PIP2. C. Kinetic studies on PI3K reaction with BODIPY-PIP2. Each experiment was
carried out in duplicate and repeated three times.
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Measurement of KM for ATP for the PI3K reactions with FL-PIP2 (A) or BODIPY-PIP2 (B)
as the lipid substrate. Each experiment was carried out in duplicate and repeated three times.
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Dose response curves of PI3K inhibitors LY294002 and wortmannin. A. IC50 values of
LY294002 and wortmannin were measured with FL-PIP2 as the PI3K substrate; B. IC50
values of LY294002 and wortmannin were measured with BODIPY-PIP2 as the PI3K
substrate. Each experiment was carried out in duplicate and repeated three times.
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